Navigating Systemic Psoriasis Therapies and Skin Cancer Risk: New JDD Insights
Have you read this article from the JDD? For clinicians managing moderate to severe psoriasis, balancing long term disease control with systemic safety remains a core priority. A newly published real world analysis in the Journal of Drugs in Dermatology evaluates how different systemic interventions compare regarding cutaneous malignancy risks.
While traditional immunosuppressants and early generation biologics are often discussed in the context of skin cancer surveillance, newer targeted pathways present a far more nuanced picture. Investigators analyzed extensive multiyear patient data from the TriNetX database, examining cohorts on cyclosporine, methotrexate, TNF alpha inhibitors, IL 12/23, IL 17, and IL 23 therapies against non systemically treated controls.
The findings highlight notable variations across drug classes for nonmelanoma skin cancer and melanoma over 2 year and 5 year treatment intervals. While conventional systemic agents showed predictable elevations in skin malignancy outcomes, specific targeted cytokine inhibitors demonstrated significantly lower risk profiles. Understanding these key class distinctions allows dermatology providers to better tailor systemic selection for higher risk patients.
Review the full study in the latest issue of the JDD to explore the complete hazard ratio data, secondary cohort comparisons, and study limitations for your clinical practice.
Blog write-up assisted by AI
